This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
ALS patients experience neuroinflammation and rapid neurodegeneration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
It is a novel oral NLRP3 inflammasome inhibitor
Subscribe To Our Newsletter & Stay Updated
